Certain oncogenic mutations in BRAF cause the BRAF proteins to become activated on their own, permanently activating MEK1/2 and ERK1/2 via the MAPK pathway and promoting the formation of tumours [45]. The gene discussed is BRAF; the disease is neoplasm.